#France #EMEA #Marseille #Terumo Neuro #Aneurysm Treatment

Terumo Neuro Launches New Alliance for Aneurysm Treatment in EMEA

In a significant step aimed at enhancing medical collaboration and treatment effectiveness, Terumo Neuro has announced the launch of the Aneurysm Treatment Alliance during the 17th Annual Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT) 2025.

Overview of Terumo Neuro

As a global leader in neurovascular innovations and a wholly-owned subsidiary of Terumo Corporation, Terumo Neuro is dedicated to redefining possibilities in the treatment of neurovascular conditions. Founded in 1997 and acquired by Terumo in 2006, the company has developed over thirty products addressing critical conditions such as cerebral aneurysms, ischemic strokes, and vascular malformations. Today, their products are marketed in more than seventy countries worldwide.

The Aneurysm Treatment Alliance

The Aneurysm Treatment Alliance is specifically created to bolster cooperation among healthcare professionals across the EMEA region. This initiative aims to streamline collaboration processes and showcase Terumo Neuro's unique product portfolio designed for managing aneurysms effectively. The key components of the Alliance include:

• - Comprehensive Product Access: Participants will have full access to Terumo Neuro's bleeding management product lineup, including leading therapies such as the WEB™ device, LVIS™ EVO stent, FRED™ X flow diverter, hydrogel coils, and pure platinum coils, all recognized in the industry for their clinical efficacy.

• - Fostering Collaboration: The Alliance will deepen interactions with medical professionals, going beyond traditional presentations to prioritize shared experiences, inter-regional insights, and ongoing dialogues that lead to clinical advancements.

• - Regional Learning: The initiative will improve knowledge sharing and best practices across EMEA, enhancing medical interactions and the quality of care provided.

• - Cross-Collaboration Opportunities: This will expand education and training about integrated implantable device solutions relevant to aneurysm management, ensuring that medical professionals are well-equipped to address diverse patient needs.

Sebastien Chabeauti, Vice President and General Manager of Terumo Neuro for EMEA, emphasized the significance of this Alliance: “Our bleeding management product portfolio is groundbreaking, allowing physicians to treat a wide range of aneurysms confidently. The Aneurysm Treatment Alliance solidifies our commitment to equipping EMEA’s doctors with practical tools and collaboration opportunities aimed at improving aneurysm care outcomes.”

Commitment to Innovation

Terumo Neuro's initiative reflects its decade-long dedication to fostering physician collaboration, innovative solutions, and improved patient outcomes globally. As a company with a storied history and a robust commitment to neurovascular care, Terumo Neuro stands at the forefront of technological advancements that shape the future of medicine.

For further information about their commitment to medical innovation, visit Terumo Neuro's official website. With operations headquartered in California, Terumo's manufacturing facilities extend to San José, Costa Rica, underlining its global reach in providing essential medical technologies.

About Terumo Corporation

Established for over a century, Terumo Corporation is a worldwide leader in medical technologies. With approximately 30,000 employees across the globe, the company focuses on delivering innovative medical solutions in over 160 countries and regions. From its origins as a thermometer manufacturer to its comprehensive range of vascular interventions and critical clinical products, Terumo’s impact on global health continues to grow significantly.

For media inquiries:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+1 714 206 9800
Email: [email protected]